View in EDS HTML Full Text PDF Full Text

A novel and safe SmartCap® SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans.

Saved in:
Bibliographic Details
Title: A novel and safe SmartCap® SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans.
Authors: Kim R; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Uhm TG; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim J; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Woo D; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim UI; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Meng X; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Yang B; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim S; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim H; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim J; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Yoon S; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea., Lee JY; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim B; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Cho D; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Chang D; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Cho YH; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Choi K; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Gwak W; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea., Lee HW; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Bang J; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Hellström E; Be Part Research (PTY) Ltd., Paarl, South Africa., Kim B; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea., Kim K; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Yang JS; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Source: Frontiers in immunology [Front Immunol] 2025 Jun 16; Vol. 16, pp. 1571092. Date of Electronic Publication: 2025 Jun 16 (Print Publication: 2025).
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40589754
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A novel and safe SmartCap<superscript>®</superscript> SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kim+R%22">Kim R</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Uhm+TG%22">Uhm TG</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+J%22">Kim J</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Woo+D%22">Woo D</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+UI%22">Kim UI</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Meng+X%22">Meng X</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yang+B%22">Yang B</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+S%22">Kim S</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+H%22">Kim H</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+J%22">Kim J</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yoon+S%22">Yoon S</searchLink>; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+JY%22">Lee JY</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+B%22">Kim B</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cho+D%22">Cho D</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Chang+D%22">Chang D</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cho+YH%22">Cho YH</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Choi+K%22">Choi K</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Gwak+W%22">Gwak W</searchLink>; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+HW%22">Lee HW</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Bang+J%22">Bang J</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Hellström+E%22">Hellström E</searchLink>; Be Part Research (PTY) Ltd., Paarl, South Africa.<br /><searchLink fieldCode="AU" term="%22Kim+B%22">Kim B</searchLink>; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+K%22">Kim K</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yang+JS%22">Yang JS</searchLink>; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2025 Jun 16; Vol. 16, pp. 1571092. <i>Date of Electronic Publication: </i>2025 Jun 16 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40589754
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2025.1571092
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1571092
    Titles:
      – TitleFull: A novel and safe SmartCap® SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kim R
      – PersonEntity:
          Name:
            NameFull: Uhm TG
      – PersonEntity:
          Name:
            NameFull: Kim J
      – PersonEntity:
          Name:
            NameFull: Woo D
      – PersonEntity:
          Name:
            NameFull: Kim UI
      – PersonEntity:
          Name:
            NameFull: Meng X
      – PersonEntity:
          Name:
            NameFull: Yang B
      – PersonEntity:
          Name:
            NameFull: Kim S
      – PersonEntity:
          Name:
            NameFull: Kim H
      – PersonEntity:
          Name:
            NameFull: Kim J
      – PersonEntity:
          Name:
            NameFull: Yoon S
      – PersonEntity:
          Name:
            NameFull: Lee JY
      – PersonEntity:
          Name:
            NameFull: Kim B
      – PersonEntity:
          Name:
            NameFull: Cho D
      – PersonEntity:
          Name:
            NameFull: Chang D
      – PersonEntity:
          Name:
            NameFull: Cho YH
      – PersonEntity:
          Name:
            NameFull: Choi K
      – PersonEntity:
          Name:
            NameFull: Gwak W
      – PersonEntity:
          Name:
            NameFull: Lee HW
      – PersonEntity:
          Name:
            NameFull: Bang J
      – PersonEntity:
          Name:
            NameFull: Hellström E
      – PersonEntity:
          Name:
            NameFull: Kim B
      – PersonEntity:
          Name:
            NameFull: Kim K
      – PersonEntity:
          Name:
            NameFull: Yang JS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 06
              Text: 2025 Jun 16
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1